BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sasaki R, Kanda T, Fujisawa M, Matsumoto N, Masuzaki R, Ogawa M, Matsuoka S, Kuroda K, Moriyama M. Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll-Like Receptor-Signaling Pathways in Human Hepatoma Cell Lines. Int J Mol Sci 2020;21:E3349. [PMID: 32397371 DOI: 10.3390/ijms21093349] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Odagiri N, Hai H, Thuy LTT, Dong MP, Suoh M, Kotani K, Hagihara A, Uchida-Kobayashi S, Tamori A, Enomoto M, Kawada N. Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization. Cancers (Basel) 2020;12:E2045. [PMID: 32722224 DOI: 10.3390/cancers12082045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
2 Liu L, Liu B, Yu J, Zhang D, Shi J, Liang P. Development of a Toll-Like Receptor-Based Gene Signature That Can Predict Prognosis, Tumor Microenvironment, and Chemotherapy Response for Hepatocellular Carcinoma. Front Mol Biosci 2021;8:729789. [PMID: 34621787 DOI: 10.3389/fmolb.2021.729789] [Reference Citation Analysis]
3 Bartsch LM, Damasio MPS, Subudhi S, Drescher HK. Tissue-Resident Memory T Cells in the Liver-Unique Characteristics of Local Specialists. Cells 2020;9:E2457. [PMID: 33187162 DOI: 10.3390/cells9112457] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Tan W, Zhang K, Chen X, Yang L, Zhu S, Wei Y, Xie Z, Chen Y, Shang C. GPX2 is a potential therapeutic target to induce cell apoptosis in lenvatinib against hepatocellular carcinoma. Journal of Advanced Research 2022. [DOI: 10.1016/j.jare.2022.03.012] [Reference Citation Analysis]
5 Zhang K, Liu H, Yu M, Zhao H, Yang N, Bi X, Sun L, Lin R, Lü G. Upregulated LINC01667 Expression Is Correlated With Poor Prognosis in Hepatocellular Carcinoma. Front Oncol 2021;11:650173. [PMID: 34458133 DOI: 10.3389/fonc.2021.650173] [Reference Citation Analysis]
6 Dahiya M, Dureja H. Sorafenib for hepatocellular carcinoma: potential molecular targets and resistance mechanisms. J Chemother 2021;:1-16. [PMID: 34291704 DOI: 10.1080/1120009X.2021.1955202] [Reference Citation Analysis]
7 Xin Y, Zheng T, Zhang M, Zhang R, Zhu S, Li D, Zhao D, Ma Y, Ho C, Huang Q. Demethylnobiletin and its major metabolites: Efficient preparation and mechanism of their anti-proliferation activity in HepG2 cells. Food Science and Human Wellness 2022;11:1191-200. [DOI: 10.1016/j.fshw.2022.04.018] [Reference Citation Analysis]
8 Yang Q, Gao L, Huang X, Weng J, Chen Y, Lin S, Yin Q. Sorafenib prevents the proliferation and induces the apoptosis of liver cancer cells by regulating autophagy and hypoxia-inducible factor-1. Exp Ther Med 2021;22:980. [PMID: 34345262 DOI: 10.3892/etm.2021.10412] [Reference Citation Analysis]
9 Chi G, Pei JH, Li XQ. RAE1 is a prognostic biomarker and is correlated with clinicopathological characteristics of patients with hepatocellular carcinoma. BMC Bioinformatics 2022;23:252. [PMID: 35751040 DOI: 10.1186/s12859-022-04806-8] [Reference Citation Analysis]